NCT03670069View on ClinicalTrials.gov

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

March 4, 2023

Study Completion Date

May 6, 2024

Conditions
Metastatic LeiomyosarcomaMetastatic Synovial SarcomaMetastatic Undifferentiated Pleomorphic SarcomaAdvanced Myxoid LiposarcomaAdvanced Soft Tissue SarcomaMetastatic Myxoid LiposarcomaMetastatic Round Cell LiposarcomaMetastatic Soft Tissue SarcomaRefractory LeiomyosarcomaRefractory Myxoid LiposarcomaRefractory Round Cell LiposarcomaRefractory Soft Tissue SarcomaRefractory Synovial SarcomaRefractory Undifferentiated Pleomorphic SarcomaAdvanced LeiomyosarcomaAdvanced Synovial SarcomaAdvanced Undifferentiated Pleomorphic SarcomaMetastatic Chondrosarcoma
Interventions
DRUG

Itacitinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER